0001144204-18-049515.txt : 20180914 0001144204-18-049515.hdr.sgml : 20180914 20180914163018 ACCESSION NUMBER: 0001144204-18-049515 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180913 FILED AS OF DATE: 20180914 DATE AS OF CHANGE: 20180914 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Shaaltiel Yoseph CENTRAL INDEX KEY: 0001385118 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33357 FILM NUMBER: 181071468 MAIL ADDRESS: STREET 1: C/O PROTALIX BIOTHERAPEUTICS, INC. STREET 2: 2 SNUNIT ST, SCIENCE PARK, POB 455 CITY: CARMIEL STATE: L3 ZIP: 20100 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Protalix BioTherapeutics, Inc. CENTRAL INDEX KEY: 0001006281 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 650643773 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2 SNUNIT ST STREET 2: SCIENCE PARK, POB 455 CITY: CARMIEL STATE: L3 ZIP: 20100 BUSINESS PHONE: 972-4-988-9488 MAIL ADDRESS: STREET 1: 2 SNUNIT ST STREET 2: SCIENCE PARK, POB 455 CITY: CARMIEL STATE: L3 ZIP: 20100 FORMER COMPANY: FORMER CONFORMED NAME: ORTHODONTIX INC DATE OF NAME CHANGE: 19980422 FORMER COMPANY: FORMER CONFORMED NAME: EMBASSY ACQUISITION CORP DATE OF NAME CHANGE: 19960124 4 1 tv502880_4.xml OWNERSHIP DOCUMENT X0306 4 2018-09-13 0 0001006281 Protalix BioTherapeutics, Inc. PLX 0001385118 Shaaltiel Yoseph C/O PROTALIX BIOTHERAPEUTICS, INC. 2 SNUNIT ST, SCIENCE PARK, POB 455 CARMIEL L3 20100 ISRAEL 0 1 0 0 Executive VP, R&D Stock Options (Right to Buy) 0.56 2018-09-13 4 A 0 700000 0 A 2028-09-13 Common Stock 700000 700000 D The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended. Does not include (i) options to purchase 50,000 shares of common stock at an exercise price equal to $2.65 per share that expire on February 25, 2019; (ii) options to purchase 145,000 shares of common stock at an exercise price equal to $6.90 per share that expire on February 25, 2020; and (iii) options to purchase 275,000 shares of common stock at an exercise price equal to $1.72 per share that expire on March 23, 2025. /s/ Yossi Maimon, POA 2018-09-14